Skip to content
Review

[Molecular biomarkers for multiple system atrophy. (A systematic review)].

Nov 2026 · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Vol 126 10. Vyp. 2, pp. 33-40 · 0 citations · 57 references
Medicine

TL;DR

This systematic review synthesizes current evidence on molecular biomarkers of MSA in biological fluids, including cerebrospinal fluid and blood plasma, and critically assesses their pathophysiological relevance, differential diagnostic and prognostic value, and the limitations and inconsistencies that hinder clinical implementation.

Abstract

Multiple system atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder. Early diagnosis remains challenging because of clinical heterogeneity and symptom overlap with Parkinson's disease and other atypical parkinsonian syndromes. This systematic review synthesizes current evidence on molecular biomarkers of MSA in biological fluids, including cerebrospinal fluid and blood plasma, following PRISMA 2020 guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). It evaluates seven groups of potential biomarkers: aggregated α-synuclein, neurofilament light chains, tau protein, myelin basic protein, neurotransmitters (dopamine, norepinephrine, serotonin, β-endorphins), neuroinflammation markers (cytokines, c), homocysteine, and coenzyme Q10. The review critically assesses their pathophysiological relevance, differential diagnostic and prognostic value, and the limitations and inconsistencies that hinder clinical implementation. It also discusses promising strategies for combining biomarkers.

View source

Similar papers

Review Open access Oct 2026

Blood-Based Biomarkers Reveal Molecular Overlap Between Alzheimer's and Parkinson's Disease: A Comprehensive Review

Alzheimer’s disease (AD) and Parkinson’s disease (PD) together affect over 65 million people worldwide, yet no disease-modifying treatment exists for either condition. For decades, they were studied as separate entities, involving different proteins, different brain regions, and different clinical teams. Blood- based b...

Shiven Bansal · 0 citations
Open access 2026

Cerebrospinal Fluid Neuroinflammatory Biomarkers and Motor Symptom Severity in Early-Stage Parkinson’s Disease: A Cross-Sectional Analysis of the PPMI Cohort

It is suggested that CSF neuroinflammatory biomarkers were not associated with early motor severity in this sample of early-stage PD patients, and future research should examine whether these markers are more closely associated with other domains such as cognitive decline.

Harshal Lingineni · 0 citations
Open access Oct 2026

Neuropsychiatric and Cognitive Symptom Evolution over the First Decade of Biomarker-Positive, Sporadic Parkinson's Disease.

BACKGROUND Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co-occur. Their long-term evolution remains incompletely characterized, particularly in biomarker-positive cohorts. OBJECTIVE The aim was to examine the evolut...

Izabelle Schoen, Jing Wang, Sharon X. Xie et al. · 0 citations
Review Open access Oct 2026

Blood biomarkers in the early diagnosis of Alzheimer’s disease: an integrative literature review

Background: Alzheimer’s disease (AD) is characterized by extracellular amyloid-beta accumulation and intracellular neurofibrillary tangles composed of hyperphosphorylated tau, changes that precede cognitive decline by years. Although diagnostic methods have advanced, gold-standard techniques such as positron emission t...

Eduarda Viana Silva, Iury Hélder Santos Dantas, Ingrid Yasmim Farias de Melo Yasmim Farias de Melo et al. · 0 citations
Open access Oct 2026

Clinical and biomarker predictors of α-synuclein seeding in cognitive impairment and motor parkinsonism.

Dopamine transporter (DAT) imaging and α-synuclein seed amplification assay (SAA) are biomarkers for Lewy body disease (LBD). We aimed to identify clinical and biomarker factors associated with SAA positivity in patients with cognitive impairment and frequent motor parkinsonism. Dual-phase DAT positron emission tomogra...

Byoung Seok Ye, Lawren VandeVrede, Su-Hee Jeon et al. · 0 citations
Review Sep 2026

Parkinson's disease diagnosis using machine learning and multimodal biomarkers: A systematic review.

Multimodal fusion architectures, particularly cross-attention transformers integrating motor, voice, and gait data, consistently outperformed unimodal approaches by 4%-8% in the area under the receiver operating characteristic curve (AUC), with the largest gains in early stage detection and differential diagnosis tasks...

Muhammad Imran Khan, A. Imran, A. Alshammari · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.